Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited (IMMP) is a clinical-stage biotechnology leader pioneering LAG-3 immunotherapies for cancer and autoimmune diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Key resources include: Press releases detailing trial results for therapies like IMP321 and IMP701, financial disclosures from global exchanges, partnership announcements with major pharmaceutical collaborators, and scientific presentations demonstrating LAG-3 innovation. All content is sourced directly from company filings and verified channels.
Bookmark this page for streamlined access to Immutep's latest developments in immuno-oncology research, including updates from ongoing clinical programs and analyses of emerging therapeutic strategies. Check regularly for real-time insights into one of biotech's most active immunotherapy pipelines.
Immutep Limited (NASDAQ: IMMP) announced a significant update on its collaboration with Cardiff University to develop a new generation of small molecule anti-LAG-3 therapies aimed at providing affordable oral treatments for cancer patients. This project, leveraging Immutep's expertise in LAG-3 biology and Cardiff's medicinal chemistry skills, aims to produce compounds with lower costs compared to existing antibodies. The joint venture will result in shared intellectual property, enabling Immutep exclusive rights to develop these novel therapeutic molecules commercially.
Immutep Limited announced positive final data from its Phase I INSIGHT-004 study, revealing a 41.7% objective response rate and 50% disease control rate among 12 patients with various solid tumors. Notably, 75% of patients remain alive. The study evaluated the combination of eftilagimod alpha and avelumab, demonstrating encouraging activity even in patients with low PD-L1 expression. The treatment maintained a good safety profile with no dose-limiting toxicities, supporting further clinical evaluation of this novel therapy.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced positive interim data from the Phase II TACTI-002 study, demonstrating a 41.7% overall response rate (ORR) for first-line non-small cell lung cancer (NSCLC) and 29.7% ORR for second-line head and neck squamous cell carcinoma (HNSCC). The study showed significant tumor responses across PD-L1 subgroups, with safe and well-tolerated results. The median progression-free survival (PFS) was 8.2 months for NSCLC and 12.6 months for HNSCC. Further recruitment into the trial is ongoing, promising advancements in treatment.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the grant of a new European patent (EP3473263) for combined preparations in cancer treatment. This patent follows previous grants in November 2018 and early 2021, enhancing the protection of their lead candidate eftilagimod alpha (IMP321) alongside PD-1/PD-L1 inhibitors. Valid until January 8, 2036, this patent reinforces Immutep's commitment to clinical development and commercialization of innovative therapies. CEO Marc Voigt highlighted the patent's importance for ongoing trials, especially those presented at the upcoming ASCO 2021 Annual Meeting.
Immutep Limited (NASDAQ: IMMP) announced a collaboration with Merck KGaA for a Phase I/IIa clinical trial named INSIGHT-005, focusing on eftilagimod alpha in combination with bintrafusp alfa in previously treated patients with solid tumours. This new trial builds on previous encouraging data from the INSIGHT trial. The first patient is set to be enrolled in mid-2021, with initial data expected by early 2022. The study aims to investigate the safety and efficacy of this combination therapy, enhancing Immutep's ongoing relationship with Merck.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the grant of a new patent by the Chinese Patent Office for its combination therapy involving eftilagimod alpha and chemotherapy agents like oxaliplatin. This adds to existing patents in Europe, Australia, Japan, and the U.S., enhancing Immutep's intellectual property rights in China until December 19, 2034. EOC Pharma, Immutep's partner in China, will develop this therapy, highlighting increasing collaboration in the oncology sector.
Immutep Limited (NASDAQ: IMMP) announced that CEO Marc Voigt will present at the Jefferies Virtual Healthcare Conference from June 1-4, 2021. The corporate presentation, alongside Chief Scientific and Medical Officer Dr. Frederic Triebel, is scheduled for June 4 at 12:30 PM ET. A live webcast will be available for the event. Immutep is focused on developing immunotherapy treatments for cancer and autoimmune diseases, with its lead product candidate being eftilagimod alpha (IMP321), which activates antigen presenting cells.
Immutep Limited (NASDAQ: IMMP) announced new data from its TACTI-002 and INSIGHT-004 studies presented at the 2021 ASCO Annual Meeting. The TACTI-002 study focused on eftilagimod alpha's efficacy as an immunotherapy for metastatic non-small cell lung cancer and squamous head and neck carcinoma. Meanwhile, the INSIGHT-004 trial evaluated the safety of eftilagimod alpha with avelumab in advanced solid tumors. These studies represent significant advancements in Immutep's ongoing research into LAG-3 related cancer treatments, potentially enhancing investor interest.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) provided a significant update on its clinical trials, notably AIPAC and TACTI-002, reporting that AIPAC has reached 72% of events and TACTI-002 is progressing well with 54 patients enrolled. New data from these studies is expected to be presented at ASCO in June 2021. The TACTI-003 trial, evaluating efti with pembrolizumab, aims to start mid-2021, while the company maintains a robust financial position with a cash runway extending into 2023.
Immutep Limited (NASDAQ: IMMP) announced new data from its TACTI-002 and INSIGHT-004 studies, to be presented during the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting from June 4-8. This includes three poster presentations focused on the efficacy of eftilagimod alpha in combination with pembrolizumab and avelumab across various cancers. The abstracts will be available on May 19, with further data shared in a subsequent webcast. These studies are pivotal in advancing LAG-3 immunotherapy treatments for cancer.
